| Identification | Back Directory | [Name]
Hexanoic acid, 6-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-, 1,1-dimethylethyl ester | [CAS]
2226139-38-2 | [Synonyms]
Thalidomide-4-NH-C5-COO(t-Bu)
2-(2,6-Dioxohexahydropyridin-3-yl)-4-(hexylamino)isoindole-1,3-dione
tert-butyl 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoate
Hexanoic acid, 6-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-, 1,1-dimethylethyl ester | [Molecular Formula]
C23H29N3O6 | [MOL File]
2226139-38-2.mol | [Molecular Weight]
443.49 |
| Hazard Information | Back Directory | [Uses]
Thalidomide-NH-C4-Boc is the conjugate composed of an E3 ligase (Cereblon) ligand and a linker that can be used for synthesis of PROTAC CARM1/IKZF3 degrader-1 (HY-172368)[1]. | [References]
[1] Ni W, et al. Dual CARM1-and IKZF3-targeting: a novel approach to multiple myeloma therapy Synergy between CARM1 inhibition and IMiDs[J]. Molecular Therapy Oncology, 2025. |
|
|